{
    "2019-09-05": [
        [
            {
                "time": "2019-09-05",
                "original_text": "Health Care Sector Update for 09/05/2019: MNK, ZFGN, LVGO, JNJ, PFE, MRK, ABT, AMGN",
                "features": {
                    "keywords": [
                        "Health Care Sector",
                        "MNK",
                        "ZFGN",
                        "LVGO",
                        "JNJ",
                        "PFE",
                        "MRK",
                        "ABT",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "Merck's Keytruda Combination Gets EC Nod for Kidney Cancer",
                "features": {
                    "keywords": [
                        "Merck",
                        "Keytruda",
                        "EC Nod",
                        "Kidney Cancer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "J&J's Stelara Gets Approval in EU for Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "J&J",
                        "Stelara",
                        "Approval",
                        "EU",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "How Important Is Keytruda For Merck?",
                "features": {
                    "keywords": [
                        "Keytruda",
                        "Merck"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "Can Biosimilars Be The Next Growth Driver For Pfizer?",
                "features": {
                    "keywords": [
                        "Biosimilars",
                        "Growth Driver",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?",
                "features": {
                    "keywords": [
                        "FDA",
                        "Diabetes Drug",
                        "$2.9 Billion"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-09-05",
                "original_text": "Special Situations Gurus Are Buying",
                "features": {
                    "keywords": [
                        "Special Situations",
                        "Gurus",
                        "Buying"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}